LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

Search

MannKind Corp

Open

SectorHealthcare

4.42 -3.07

Overview

Share price change

24h

Current

Min

4.35

Max

4.57

Key metrics

By Trading Economics

Income

5.7M

13M

Sales

1.6M

78M

P/E

Sector Avg

48.1

56.602

EPS

0.04

Profit margin

16.793

Employees

403

EBITDA

8.3M

27M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+119.3% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-45M

1.5B

Previous open

7.49

Previous close

4.42

News Sentiment

By Acuity

38%

62%

130 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

15 May 2025, 22:52 UTC

Earnings
Major Market Movers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 May 2025, 20:37 UTC

Top News
Earnings

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 May 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 May 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 May 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 May 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 May 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 May 2025, 22:46 UTC

Top News
Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 May 2025, 21:58 UTC

Earnings

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 May 2025, 21:24 UTC

Earnings

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 May 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 May 2025, 20:54 UTC

Market Talk
Earnings

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 May 2025, 20:54 UTC

Earnings

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 May 2025, 20:51 UTC

Earnings

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 May 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 May 2025, 20:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 May 2025, 20:50 UTC

Earnings

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 May 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 May 2025, 20:25 UTC

Earnings

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

119.3% upside

12 Months Forecast

Average 10 USD  119.3%

High 12 USD

Low 9 USD

Based on 6 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

130 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.